Advertisement

#Tagrisso

FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer

Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.

Tagrisso

Scan Results and the One Question Nobody Asks

If your life depends on it, wouldn’t you want to know EVERYTHING that might help?

Osimertinib binds to specific mutated forms of EGFR proteins, including one called T790M that is linked to resistance to other EGFR-targeted drugs.

Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations

The survival improvement did not come at the cost of safety; the investigators saw no increase in serious side effects.

What Is Targeted Therapy?

Precision medicine matches patients with the treatments most likely to work for them.

FDA Approves Tagrisso for First-Line Lung Cancer Treatment

Osimertinib led to improved progression-free survival in people with common EGFR mutations.

Advertisement